UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform
Computational advancements enable earlier and more widespread use of antibody-antigen structural insights across drug discovery process These advancements have the potential to transform antibody discovery methods, broadening therapeutic applications and accelerating the development of… Read More »UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform